- Conditions
- Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
- Interventions
- Solriamfetol 150 MG, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Bellflower, California • Chino, California + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
- Conditions
- ADHD
- Interventions
- Solriamfetol
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Dothan, Alabama • Maitland, Florida • Memphis, Tennessee
- Conditions
- ADHD
- Interventions
- Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Encino, California • Garden Grove, California • Newport Beach, California + 37 more
- Conditions
- Major Depressive Disorder
- Interventions
- Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 40
- States / cities
- Little Rock, Arkansas • Bellflower, California • Encino, California + 35 more
- Conditions
- Multiple Sclerosis, Multiple Sclerosis Fatigue
- Interventions
- Solriamfetol, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
- Interventions
- Solriamfetol Oral Tablet [Sunosi], Placebo
- Drug
- Lead sponsor
- Rochester Center for Behavioral Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester Hills, Michigan
- Conditions
- Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
- Interventions
- Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants, No treatment
- Drug · Other
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 1,731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 2
- States / cities
- Morrisville, North Carolina • Wilmington, North Carolina
- Conditions
- Excessive Sleepiness, Shift-work Disorder
- Interventions
- Solriamfetol Oral Tablet, Placebo
- Drug
- Lead sponsor
- Charles A. Czeisler, PhD, MD
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- ADHD
- Interventions
- Solriamfetol Dose A, Solriamfetol Dose B, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 24
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Irvine, California + 21 more
- Conditions
- Insomnia
- Interventions
- Solriamfetol 75 MG, Cognitive Behavioral Therapy for Insomnia (CBT-I), Monitoring, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 25 Years to 60 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Solriamfetol 75 MG, Solriamfetol 150 MG, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum
- Interventions
- Solriamfetol 150 mg Oral Tablet
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Binge Eating Disorder
- Interventions
- Solriamfetol, Placebo
- Drug
- Lead sponsor
- Lindner Center of HOPE
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Mason, Ohio
- Conditions
- Binge-Eating Disorder
- Interventions
- Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Encino, California • Garden Grove, California • Long Beach, California + 38 more
- Conditions
- ADHD
- Interventions
- Solriamfetol Dose A, Solriamfetol Dose B, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Irvine, California + 20 more
- Conditions
- Binge-Eating Disorder
- Interventions
- Solriamfetol, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 56 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 33
- States / cities
- Encino, California • Long Beach, California • Santa Ana, California + 28 more
- Conditions
- Excessive Sleepiness, Shift-work Disorder
- Interventions
- Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Auburn, Alabama • Cullman, Alabama • Chandler, Arizona + 37 more